Stock CIR NIOX GROUP PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials NIOX Group Plc

Equities

CIR

GB00BJVD3B28

Pharmaceuticals

Market Closed - London S.E.
Other stock markets
 11:35:20 2024-04-26 am EDT 		5-day change 1st Jan Change
66.6 GBX -1.48% Intraday chart for NIOX Group Plc +3.10% -0.60%
Apr. 04 NIOX Group Plc Proposes Final Dividend for the Financial Year Ended 31 December 2023, Payable on 24 June 2024 CI
Mar. 26 EARNINGS: CAB Payments profit drops, Life Science REIT cuts dividend AN

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 71.18 111.9 169.6 153.1 281.9 282.4 - -
Enterprise Value (EV) 1 156.2 104.5 158.3 134.7 263.1 254.6 246 236.1
P/E ratio -1.46 x - 40.6 x 10.1 x 28.2 x 23.8 x 19.9 x 17.3 x
Yield - - - - 1.49% 1.62% 2.03% 2.24%
Capitalization / Revenue 1.14 x 2.43 x 6.08 x 4.89 x 7.66 x 6.66 x 5.83 x 5.23 x
EV / Revenue 2.5 x 2.27 x 5.67 x 4.3 x 7.15 x 6.01 x 5.08 x 4.37 x
EV / EBITDA -5.62 x -9.42 x 264 x 18.5 x 23.1 x 19.3 x 15.1 x 12.8 x
EV / FCF -4.46 x - 122 x 20.4 x 22.9 x 18.6 x 17.5 x 14.2 x
FCF Yield -22.4% - 0.82% 4.9% 4.37% 5.37% 5.71% 7.05%
Price to Book 0.84 x - 2.54 x 1.87 x 3.59 x 3.13 x 2.85 x 2.72 x
Nbr of stocks (in thousands) 374,655 396,836 417,684 419,504 420,684 423,971 - -
Reference price 2 0.1900 0.2820 0.4060 0.3650 0.6700 0.6660 0.6660 0.6660
Announcement Date 6/16/20 3/24/21 3/22/22 3/21/23 3/26/24 - - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 62.4 46 27.9 31.3 36.8 42.37 48.43 54.02
EBITDA 1 -27.8 -11.1 0.6 7.3 11.4 13.18 16.29 18.5
EBIT 1 -43 -17.3 -4.3 1.8 4.6 8.224 11.51 13.71
Operating Margin -68.91% -37.61% -15.41% 5.75% 12.5% 19.41% 23.77% 25.38%
Earnings before Tax (EBT) 1 -59.1 -18.4 -2.1 10.5 4.1 9.001 11.22 13.49
Net income 1 -48.3 - 3.6 16.1 10.7 12.8 14.5 16.55
Net margin -77.4% - 12.9% 51.44% 29.08% 30.21% 29.94% 30.64%
EPS 2 -0.1300 - 0.0100 0.0363 0.0238 0.0280 0.0335 0.0385
Free Cash Flow 1 -35 - 1.3 6.6 11.5 13.67 14.04 16.64
FCF margin -56.09% - 4.66% 21.09% 31.25% 32.27% 28.99% 30.81%
FCF Conversion (EBITDA) - - 216.67% 90.41% 100.88% 103.71% 86.2% 89.97%
FCF Conversion (Net income) - - 36.11% 40.99% 107.48% 106.82% 96.82% 100.57%
Dividend per Share 2 - - - - 0.0100 0.0108 0.0135 0.0149
Announcement Date 6/16/20 3/24/21 3/22/22 3/21/23 3/26/24 - - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 S2 2023 S1
Net sales 13.3 -
EBITDA - -
EBIT - -
Operating Margin - -
Earnings before Tax (EBT) - -
Net income - -
Net margin - -
EPS - -
Dividend per Share 1 - -
Announcement Date 3/22/22 -
1GBP
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 85 - - - - - - -
Net Cash position 1 - 7.4 11.3 18.4 18.8 27.8 36.3 46.3
Leverage (Debt/EBITDA) -3.058 x - - - - - - -
Free Cash Flow 1 -35 - 1.3 6.6 11.5 13.7 14 16.6
ROE (net income / shareholders' equity) -45.8% - - 21.7% 12.9% 13.7% 14.2% 13.8%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 0.2300 - 0.1600 0.2000 0.1900 0.2100 0.2300 0.2500
Cash Flow per Share - -0.0600 0 - - - - -
Capex 1 10.3 - - 0.1 0.1 1.03 0.75 0.55
Capex / Sales 16.51% - - 0.32% 0.27% 2.44% 1.55% 1.02%
Announcement Date 6/16/20 3/24/21 3/22/22 3/21/23 3/26/24 - - -
1GBP in Million2GBP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for NIOX Group Plc

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.666 GBP
Average target price
0.76 GBP
Spread / Average Target
+14.11%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
NIOX GROUP PLC Stock NIOX Group Plc
-0.60% 352M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CIR Stock
  4. Financials NIOX Group Plc